

Summary of Conflict of Interest Disclosure Statements  
ARIA Report 2008 Authors and Reviewers

Authors:

**Jean Bousquet** has received personal benefits for lectures and expert committees: ALK, Almirall, AstraZeneca, Aventis, Chiesi, Fabre, GlaxoSmithKline, Lehti, Merck Sharp & Dohme, Novartis, Sanofi-Aventis, Schering Plough, Stallergenes, UCB Uriach.

**Torsten Zuberbier** has acted as a consultant with Schering-Plough, UCB, MSD, Novartis, LETI, Stallergenes and Kryolan.

**Christiaan van Weel's** department has received unrestricted research and educational grants from AstraZeneca, Bayer, Novo-Nordisk, Boehringer Ingelheim, GlaxoSmithKline and Novartis.

**Michael S. Blaiss** has acted as a paid consultant for GlaxoSmithKline, Merck, Schering-Plough, UCA, Sanofi-Avantis, MedPointe and AstraZeneca. He has also participated on speaking bureaus for Merck, Schering-Plough, UCA, Sanofi-Avantis, and AstraZeneca.

**Sergio Bonini** is a Professor of Internal Medicine, Second University of Naples, Italy. He is also a research appointment at the Institute of Neurobiology and Molecular Medicine, Italian National Research Council (INMM-CNR, ARTOV), Rome, Italy; a member of the Research and Development Commission of the Italian Drug Agency (AIFA), Rome, Italy; has received research grants, consultancies, editorial activity, honoraria from participation in speakers bureau by the following companies: Alcon, Allergopharma, Allergy Therapeutics, ALK, Almirall, Aventis, AstraZeneca, Bioallergy, Bioxell, GlaxoSmithKline, Lofarma, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi-Synthelabo, Schering-Plough, Stallaergens, UCB, Zambon.

**Louis-Philippe Boulet** has worked on Advisory Boards for the following companies: Astrazeneca, GlaxoSmithKline, Novartis and Scheririg-Plough. He has received lecture fees from: Altana, Astrazeneca, GlaxoSmithKline, Merck Frosst, Novartis and MedImmune. He has received sponsorship for investigator-generated research from: AstraZeneca, GlaxoSmithKline, Merck Frosst, Schering-Plough and Novartis. He has received research funding for participating in multicenter studies from: Alexion, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Ception, GlaxoSmithKline, Generitech, IVAX, MedImmune, Novartis, Topigen, Wyeth. He has received support for the production of educational materials and initiatives from: AstraZeneca, GlaxoSmithKline and Merck Frosst. He acted as an adviser for the Conseil du Medicament du Quebec and was a member of the Quebec Workmen Compensation Board Respiratory Committee. He has been the chair of the Canadian Thoracic Society Respiratory Guidelines Committee; an ex-official member of the Board of Director of the Canadian Network of Centers of Excellence 'AllerGen', Holder of the Lava' University Chair on knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health.

**Kai-Hakon Carlsen** has received honoraria for lectures from GlaxoSmithKline and MSD.

**Adnan Custovic** has received grant/research support from GlaxoSmithKline, was a consultant for GlaxoSmithKline, UCS Pharma and ALK and was on the speaker's bureau for AstraZeneca, GlaxoSmithKline, UCB Pharma and ALK.

**Ronald Dahl** has participated in advisory boards for Pfizer, USA and Denmark; Novartis, Switzerland; Boehringer-Ingelheim, Tyskland and Denmark; Altlana, Germany now Nycomed, Denmark TEVA, Israel og, GlaxoSmithKline, UK; Fertin, Denmark; Aerovance, USA. The Department of Respiratory diseases, where he works, has received economic compensation for clinical trial projects from AstraZeneca, GlaxoSmithKline, Boehringer-Ingelheim, Pfizer, ALF-Abello, Allmiral, Novartis, Allergopharma, Stallergen, Roche.

**Stephen R. Durham** has received honoraria for giving lectures and for consulting on advisory boards for GlaxoSmithKline, ALK Abello and Schering-Plough.

**Roy Gerth van Wijk** has received fees for lectures from UCB Pharma, MSD, Alcon, Almirall and Novartis. Research has been supported by UCB Pharma and Artu Biologicals.

**Michael A. Kaliner** has participated in consultantships and Advisory Boards for: Adams, Alcon, Astra-Zeneca, Genentech, GlaxoSmithKline, Greer, Medimmune, MedPointe, Novartis-Genentech, Sanofi-Aventis, Schering-Plough, Strategic Pharmaceutical Advisors and Teva Specialty Products/ Ivax Labs. He has participated in Speakers' Bureaus for: Abbott, Alcon, GlaxoSmithKline, MedPointe, Novartis-Genentech, Sanofi-Aventis, Schering-Plough and Teva Specialty Products/ Ivax Labs. He has also received research grants from all asthma and allergy companies.

**Marek L. Kowalski** has acted as a paid member of Advisory Board to Schering Plough and Grupo.

**Eli O. Meltzer** is the co-director of Allergy, Asthma & Asthma Medical Group & research Center. He has received grant/research support from: Alcon, Allux, AstraZeneca, Boehringer Ingelheim, Capnia, Clay-Park, Critical Therapeutics, Genentech, GlaxoSmithKline, Hoffman-LaRoche, KOS, Medicinova, MedPointe, Merck, Novartis, Nycomed (Altana), Pharmaxis, Rigol, Sanofi- Aventis, Schering-Plough, Teva and Wyeth. He has worked as a consultant for Abbott, Adelphi, Alcon, Allux, Amgen, Astra- Zeneca, Capnia, Critical Therapautica, Dey, Evolutec, Genentech, GlaxoSmithKline, Greer, Inspire, KOS, MedPointe, Merck, Novartis, Nycomed (Altana), Pfizer, Rigel, Sanofi-Aventis, Schering-Plough, Shionogi, Versus and Wyeth. He has acted as a speaker for AstraZeneca, Alcon, Altana, Genentech, Genesis, GlaxoSmithKline, MedPointe, Merck, Pfizer, Sanofi-Aventis, Schering-Plough and Versus.

**Nikolaos Papadopoulos** has received fees for speaking, consulting and/or grant support from MSD, GlaxoSmithKline, AstraZeneca, Schering-Plough and UCB.

**Glenis K. Scadding** is a consultant and advisory board member for ALK, Britanniacal Pharmaceuticals, CMP Therapeutics, Group Uriach, GlaxoSmithKline, Merck, Sanofi-Aventis, Schering-Plough and UCB. She has received research funds from ALK, GlaxoSmithKline, USB, and Schering-Plough. She has also given talks for ALK, GlaxoSmithKline, Merck, Schering Plough and UCB.

**Barbara P. Yawn** has received research funding from AstraZeneca, Schering-Plough, GlaxoSmithKline and Merck for investigator initiated grants in the area of respiratory health. She has also acted as a paid consultant to Schering-Plough, Astra Zeneca, Merck and Pfizer in the area of respiratory health.

**Arzu Yorgancioglu** has contractually researched with AstraZeneca, Novartis, Boehringer-Ingelheim/Pfizer, Sanofi-Aventis and lecturers with AstraZeneca, Novartis, Boehringer-Ingelheim, Sanofi-Aventis, Abdi-Ibrahim and Merck.

The following authors declare no conflicts of interest:

Nikolai Khaltsev

Alvaro A. Cruz

Judah Denburg

Wytske J. Fokkens

Alkis Togias

Carlos E. Baena-Cagnani

G. Walter Canonica

Ioana Agache

Nadia Ait-Khaled

Claus Bachert

Philippe-J. Bousquet

Paulo Camargos

Yuzhi Chen

Pascal Demoly

Habib Douagui

Omer Kalayci

You-Young Kim

Piotr Kuna

Lan Thi Tuyet Le

Catherine Lemiere

Jing Li

Richard F. Lockey

Sandra Mavale-Manuel

Youssef Mohammad

Joaquim Mullol

Robert Naclerio

Robyn E. O'Hehir

Ken Ohta  
Solange Ouedraogo  
Susanna Palkonen  
Giovanni Passalacqua  
Ruby Pawankar  
Todor A. Popov  
Klaus F. Rabe  
Jose Rosado-Pinto  
F. Estelle R. Simons  
Elina Toskala  
Erkka Valovirta  
Paul van Cauwenberge  
De-Yun Wang  
Magnus Wickman  
Osman M. Yusuf  
Heather Zar

Review Group:

**Eric D. Bateman** has served on or currently serves on advisory board for Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kyowa Hakko, Merck, Novartis, Nycomed, Pfizer and Sanofi-Aventis and has received honoraria for educational activities organized by Altana/Nycomed, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Pfizer. His institution has received funding for research from Almirall, Altana, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Kyowa Hakko, Lilly, Merck, Novartis, Nycomed, Pfizer, Sanofi-Aventis and Schering- Plough. He chairs a safety committee for Hofflman le Roche.

**Peter Burney** has received lecture fees from AstraZeneca.

**William W. Busse** has acted as a paid consultant to Wyeth, Isis, CV Therapeutics, Pfizer, Amgen, Genentech, and Abbot, has received funding for research from Novartis, Centocor, MedImmune and GlaxoSmithKline and is on the Speaker's Bureau for Novartis, Merck, AstraZeneca and GlaxoSmithKline.

**William K. Dolen** has been a member of a speaker's bureau for Sanofi-Aventis.

**Lawrence Grouse** has worked as the Executive Director of the ARIA Initiative, and in that role he solicits donations for ARIA from multiple industry companies. This money does not go directly to him, but it does represent an apparent conflict of interest. However there is no conflict of interest for him in terms of wishing to benefit any individual company.

**Marc Humbert** has acted as a paid consultant to AstraZeneca, GSK and Novartis.

**Sebastian L. Johnston** has received research funding and or consultancy fees from:

AstraZeneca, Centocor, GlaxoSmithKline, Merck, Pfizer and Sonifi-Pasteur.

**Paul K. Keith** has received research support from ALK, Allergy Therapeutics, GSK, Jerini, Merck, Nycomed and Schering. He has also been on advisory boards and received lecture honoraria from Astra, GlaxoSmithKline, Merck, Nycomed and Schering.

**Desiree Larenas-Linnemann** has been a speaker and/or paid consultant for Schering-Plough, Merck, Sharp & Dohme, Boehringer-Ingelheim, Novartis, GlaxoSmithKline and has been a Medical Manager of Astra from 1997 -1999.

**Brian Lipworth** has received funding for studies, consulting or giving talks from UCB, Merck, AstraZeneca, Neolab, Cipla, Versus, Altana, Mundipharms, Innovata and Teva.

**David Price** has consultant arrangements with Aerocrine, Altana, GlaxosmithKline, Merck generics, Merck, Sharpe and Dohme, Schering-Plough and Teva. He or his team have received grants and research support for research in respiratory disease from the following organisations: UK National Health Service, Aerocrine, Altana Pharma, GlaxoSmithKline, Merck, Sharpe and Dohme, Novartis, Schering Plough and Teva. He has spoken for: Altana Pharma, GlaxoSmithKline, Merck, Sharpe and Dohme.

**Dennis Williams** has served on an advisory board for Sanofi-Aventis.

The following members of the review group declare no conflicts of interest:

Isabella Annesi-Maesano

Ali Ben Kheder

Daniel Adjei Boakye

Jacques Bouchard

Moira Chan-Yeung

Niels H. Chavannes

Alexander Chuchalin

Regina Emuzyte

Cathy Jackson

James P. Kemp

Jean-Michel Klossek

Jean-Luc Malo

Gailen D. Marshall

Charles Naspitz

Kristof Nekam

Bodo Niggemann

Ewa Nizankowska-Mogilnicka

Yoshitaka Okamoto

Maria Pia Orru

Paul Potter

Stuart W. Stoloff

Olivier Vandenplas

Giovanni Viegi